Multiple Sclerosis

Among these factors, having a higher degree of disability from multiple sclerosis (MS) was independently associated with higher morbidity and mortality risks from having a comorbid case of COVID-19.

Patients with multiple sclerosis have high rates of urinary and kidney infections, inpatient hospitalizations, and outpatient hospital claims, according to recent results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis annual meeting.

Investigators sought to better understand increasing price trends, including those seen among disease-modifying drugs to treat multiple sclerosis (MS) and other neurological diseases.

Preliminary study results point to a possible connection between increasing global temperatures and an increased risk of hospitalization during the course of multiple sclerosis (MS).

A systematic review and meta-analysis of studies of patients with multiple sclerosis (MS) found that mindfulness- and acceptance-based interventions did not have a significant effect on mindfulness among these patients.

Compared with adult-onset multiple sclerosis (MS), pediatric-onset MS has few treatments directed at the condition, specifically those that promote remyelination, enhance neuroprotection, and remediate cognitive deficits.

Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.

Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.

The current guidance emphasizes that the mRNA-based Pfizer/BioNTech and Moderna vaccines are safe for people with multiple sclerosis (MS) taking disease modifying therapies (DMTs).

Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.

Compared with patients with Parkinson disease, rheumatoid arthritis, or epilepsy, those with multiple sclerosis exhibited higher rates of medication adherence throughout the first year of treatment.

Investigators observed that some patients had improvements in their multiple sclerosis (MS) severity with increased sun exposure, whereas photosensitive individuals and those taking certain medications did not see the same effects.

Peer-led education was found to have a greater impact on multiple sclerosis (MS) health literacy than lecture-based education, a recent study from Iran demonstrated.

The findings suggest that this new categorization of cognitive deficits in multiple sclerosis may support clinicians in treatment choices and help tailor cognitive rehabilitation strategies, the authors said.

Periodic review of treatment safety and monitoring are necessary as medical centers increasingly use newer disease-modifying therapies earlier in the course of multiple sclerosis.

The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.

Researchers analyzed the available evidence on the treatment’s efficacy and safety profile from the RADIANCE and SUNBEAM trials.

As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.

A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.

The German multiple sclerosis (MS) study found differences by gender for some costs, but the overall economic burden of the disease was about the same.

A recent review examines the prevalence of headache among patients with multiple sclerosis, particularly migraine.

The Dutch study sought to add to what is known about the cost-effectiveness of shared decision-making in multiple sclerosis.

Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.

Prior research has found increased colon and breast cancer in patients with multiple sclerosis (MS), but that was not borne out in this current study.

Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.